The CDC this week noted what providers and parents have been seeing across the country: rising cases of a non-polio enterovirus causing severe respiratory illness and acute flaccid myelitis (AFM).
Providers should be aware of enterovirus D68 (EV-D68) causing severe respiratory illness and acute flaccid myelitis (AFM) in children and adolescents, the CDC said this week, saying that infections are rising across the country.
EV-D68 is one of more than 100 non-polio enteroviruses; it often arrives as summer turns to fall and can causes respiratory illness similar to a mild cold, or it may become more severe. It causes about 15 million infections a year in the United States.
It can also lead to AFM, with weakness and paralysis of the arms and legs. Past outbreaks of EV-D68 and AFM were seen in 2014, 2016, and 2018.
However, disease activity was low during the COVID-19 pandemic in 2020 and 2021. Over the past few weeks, news reports began popping up of children heading to the emergency department (ED) or being hospitalized with acute respiratory illness and asthma/reactive airway disease.
Surveillance data released Tuesday bore those reports out. The data shows that positive test results for rhinovirus/enterovirus “appears to be increasing at a rate comparable to that in past EV-D68 outbreak years,” doubling in a period of a few weeks through early September, the CDC said.
“Clinicians are advised to consider EV-D68 as a possible cause of severe respiratory illness in children and adolescents, particularly those with wheezing or who require respiratory support,” the CDC said.
In addition to testing for AFM, health care providers are urged to test for poliovirus, which has been found in New York wastewater.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More